英国新冠疫情期间免疫性血小板减少症管理的真实世界研究
结果显示糖皮质激素仍是ITP治疗的主要手段,但血小板生成素受体激动剂(TPO-RA)更有效;
要点
- 糖皮质激素仍是ITP治疗的主要手段,但TPO-RA显示出更好的疗效。
- WHO建议避免使用类固醇,NHS England支持超说明书使用TPO-RA治疗新诊断或复发性ITP。
核心结论
- 在新冠疫情期间,糖皮质激素仍是ITP治疗的主要手段,但TPO-RA更有效。
主要发现
- 糖皮质激素仍是ITP治疗的主要手段,但TPO-RA更有效。
关键数值与推荐
- WHO建议避免使用类固醇,NHS England支持超说明书使用TPO-RA治疗新诊断或复发性ITP。
临床怎么用
- 临床上可考虑将TPO-RA作为ITP的治疗选择,尤其在需避免类固醇的情况下。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has created many challenges in the management of immune thrombocytopenic purpura (ITP). The recommendation for avoidance of steroids by WHO led to the off-licence use, supported by NHS England, of thrombopoietin mimetics (TPO-RA) for newly diagnosed or relapsed ITP. This is a real-world prospective study which investigated the treatment patterns and outcomes in this setting. Twenty-four hospitals across the UK submitted 343 cases. Corticosteroids remain the mainstay of ITP treatment, but TPO-RAs were more effective. Incidental COVID-19 infection was identified in a significant number of patients (9·5%), while 14 cases were thought to be secondary to COVID-19 vaccination.
引用
- Rampotas A, Watson E, Burton K, et al. A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK. Br J Haematol. 2021. PMID: 34448203. doi:10.1111/bjh.17804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。